Related Experiment Videos

Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?

Jozefina Casuscelli¹, James J Hsieh²

¹Department of Urology, Ludwig-Maximilians University, Munich, Germany.

European Urology

|October 17, 2017

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Oncologic Outcomes in a Contemporary "PROTEUS-like" Cohort of High-risk Prostate Cancer Treated with Radical Prostatectomy Without Neoadjuvant Hormonal Therapy.

European urology open science·2026

PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal metastases after radical prostatectomy: a bi-institutional long-term outcome analysis.

European journal of nuclear medicine and molecular imaging·2026

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Cancer immunology, immunotherapy : CII·2026

Baseline Sarcopenia is Associated With Overall Survival but Not Toxicity in Patients Receiving Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.

Clinical genitourinary cancer·2026

Outcome after primary directed radiotherapy in predominantly PSMA-PET/CT-staged patients with metastatic prostate cancer.

EJNMMI research·2026

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results.

European journal of nuclear medicine and molecular imaging·2026

See all related articles